Summit Therapeutics Inc (SMMT) concluded trading on Wednesday at a closing price of $25.41, with 4.41 million shares of worth about $112.04 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 38.78% during that period and on May 21, 2025 the price saw a gain of about 4.18%. Currently the company’s common shares owned by public are about 741.61M shares, out of which, 110.45M shares are available for trading.
Stock saw a price change of 11.69% in past 5 days and over the past one month there was a price change of -7.09%. Year-to-date (YTD), SMMT shares are showing a performance of 42.39% which increased to 472.30% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.10 but also hit the highest price of $36.91 during that period. The average intraday trading volume for Summit Therapeutics Inc shares is 4.06 million. The stock is currently trading 1.01% above its 20-day simple moving average (SMA20), while that difference is up 11.58% for SMA50 and it goes to 27.84% higher than SMA200.
Summit Therapeutics Inc (NASDAQ: SMMT) currently have 741.61M outstanding shares and institutions hold larger chunk of about 13.22% of that.
The stock has a current market capitalization of $18.74B and its 3Y-monthly beta is at -0.95. It has posted earnings per share of -$0.33 in the same period. It has Quick Ratio of 10.63 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SMMT, volatility over the week remained 6.61% while standing at 11.66% over the month.
Stock’s fiscal year EPS is expected to drop by -30.93% while it is estimated to decrease by -37.48% in next year. EPS is likely to shrink at an annualized rate of -25.52% for next 5-years, compared to annual growth of -10.52% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on March 26, 2025 offering a Buy rating for the stock and assigned a target price range of between $23 and $35 to it. On March 12, 2025, Evercore ISI Initiated their recommendations, while on February 28, 2025, Goldman Initiated their ratings for the stock with a price target of $42. Stock get a Buy rating from Truist on January 08, 2025.
